Preventing Postoperative Delirium
Jacqueline Mitchell (BIDMC Communications) 617-667-7306, email@example.com
FEBRUARY 19, 2019
BIDMC Researchers Show that Intravenous acetaminophen significantly reduced the incidence of postoperative delirium following coronary artery bypass procedures in patients over 60
BOSTON – As many as half of all patients who undergo cardiac surgery may experience delirium, a form of acute confusion that can result in disorientation, impaired memory, delusions, and abrupt changes in mood and behavior, including aggression.
In a new study published in the Journal of the American Medical Association, physician-researchers at Beth Israel Deaconess Medical Center found that intravenous acetaminophen significantly reduced the incidence of postoperative delirium following coronary artery bypass procedures in patients over 60. The findings of this single-center trial may represent the first steps toward a therapeutic intervention for the prevention of postoperative delirium, a common and devastating complication in the often highly vulnerable older adults who undergo cardiac surgery.
“Currently, IV acetaminophen administration is considered an expensive intervention, and there is significant variation in pain management following cardiac surgery,” said corresponding author Balachundhar Subramaniam, MD, PhD, Director of the Center for Anesthesia Research Excellence in the Department of Anesthesia, Critical Care and Pain Medicine at BIDMC. “If our findings are replicated in a larger, multicenter study, postoperative intravenous administration of acetaminophen could become a standard of care in all cardiac surgical patients and could be incorporated in cardiac surgery recovery protocols.”
Subramaniam and colleagues enrolled 120 patients 60 years or older who underwent coronary bypass graft surgery with or without valve repair at Beth Israel Deaconess Medical Center in Boston between September 2015 and April 2018. To evaluate the effect of IV acetaminophen on postoperative delirium, the researchers randomly assigned patients into one of four groups receiving different combinations of sedation and pain medication after surgery: 29 participants received the sedative dexmedetomidine with IV acetaminophen, while 30 participants were given dexmedetomidine and placebo. Thirty-one patients were given the sedative propofol in combination with acetaminophen, and 30 received propofol with placebo.
Patients treated with acetaminophen demonstrated a significant reduction in in-hospital delirium. Only 10 percent of the group given acetaminophen experienced signs of delirium, compared to 28 percent of those given placebo. Moreover, those given acetaminophen also were more likely to have shorter stays in the intensive care unit, less breakthrough pain. Those patients who did experience delirium had shorter bouts of the acute confusion.
In addition to decreasing the incidence of delirium, adding acetaminophen to postoperative care also reduced the need for opioid painkillers in these patients, Subramaniam added.
“Postoperative pain is known to increase the risk for postoperative delirium, as is the use of opioids to manage postoperative pain,” he said. “We found that the use of IV acetaminophen provided effective pain control, and we observed a noticeable sparing of opioids in the postoperative period with decreased duration of delirium and intensive care unit length of stay.”
In addition to Subramaniam, co-investigators included Puja Shankar, Shahzad Shaefi, Ariel Mueller, Brian O’Gara, Valerie Banner-Goodspeed, Doris Gasangwa, Melissa Patxot, Senthil Packiasabapathy, Pooja Mathur, Matthias Eikermann, and Daniel Talmor, of the Department of Anesthesia, Critical Care and Pain Medicine at BIDMC; and Jackie Gallagher and Edward R. Marcantonio of the Divisions of General Medicine and Gerontology at BIDMC.
This work was supported by Mallinckrodt Pharmaceuticals, which had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.
About Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding.
BIDMC is in the community with Beth Israel Deaconess Hospital-Milton, Beth Israel Deaconess Hospital-Needham, Beth Israel Deaconess Hospital-Plymouth, Anna Jaques Hospital, Cambridge Health Alliance, Lawrence General Hospital, Signature Healthcare, Beth Israel Deaconess HealthCare, Community Care Alliance and Atrius Health. BIDMC is also clinically affiliated with the Joslin Diabetes Center and Hebrew Rehabilitation Center and is a research partner of Dana-Farber/Harvard Cancer Center and the Jackson Laboratory. BIDMC is the official hospital of the Boston Red Sox. For more information, visit www.bidmc.org.
BIDMC is part of Beth Israel Lahey Health, a new health care system that brings together academic medical centers and teaching hospitals, community and specialty hospitals, more than 4,000 physicians and 35,000 employees in a shared mission to expand access to great care and advance the science and practice of medicine through groundbreaking research and education.